• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: GENZYME CORP. SYNVISC-ONE, 48 MG

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

GENZYME CORP. SYNVISC-ONE, 48 MG Back to Search Results
Lot Number 5RSF004
Device Problem Manufacturing, Packaging or Shipping Problem (2975)
Patient Problem Missed Dose (2561)
Event Date 10/21/2018
Event Type  Injury  
Event Description
Pt reported 2 recent hospitalizations (b)(6) 2018 and (b)(6) 2018 for liver issues.(b)(6) has not sent synvisc one since (b)(6) 2016.Dose or amount: 48 mg; frequency: inject once; route: injection.Dates of use: (b)(6) 2016.Diagnosis or reason for use: osteoarthritis of knee.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SYNVISC-ONE, 48 MG
Type of Device
SYNVISC-ONE, 48 MG
Manufacturer (Section D)
GENZYME CORP.
MDR Report Key8194387
MDR Text Key131593346
Report NumberMW5082533
Device Sequence Number1
Product Code MOZ
UDI-Device Identifier58468009003
UDI-Public58468009003
Combination Product (y/n)N
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Voluntary
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 12/13/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator No Information
Device Expiration Date04/30/2018
Device Lot Number5RSF004
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? No
Initial Date Manufacturer Received Not provided
Initial Date FDA Received12/21/2018
Was Device Evaluated by Manufacturer? No Information
Type of Device Usage N
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Other;
Patient Age66 YR
-
-